By Alistair Henry (UCB)2025-04-17T10:00:23
The rise of AI, digital twins, and advanced computational modelling signals a paradigm shift in pharmaceutical R&D. These advances are poised to challenge long-standing methodologies, demanding a workforce capable of navigating an evolving technological landscape. Alistair Henry, UCB’s Chief Scientific Officer, examines how the sector needs to embrace the shift ...
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-27T15:37:00Z
Sponsored by IMA Pharma
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
2025-12-11T13:32:00
Sponsored by Hexagon
2026-03-26T15:00:00 2026-03-26T16:00:00
Sponsored by Medable
2026-05-21T14:00:00 2026-05-21T15:00:00
Sponsored by USP
Site powered by Webvision Cloud